Population Pharmacokinetic Analysis of BMS‐986166, a Novel Selective Sphingosine‐1‐Phosphate‐1 Receptor Modulator, and Exposure‐Response Assessment of Lymphocyte Counts and Heart Rate in Healthy Participants
Sébastien Bihorel(Simulations Plus (United States)), Ihab Girgis(Bristol-Myers Squibb (United States)), Jenny Xie(Bristol-Myers Squibb (United States)), John Throup(Bristol-Myers Squibb (United States)), Santanu Dutta(Bristol-Myers Squibb (United States)), Kuan‐ju Lin(Simulations Plus (United States)), Shenita Basdeo(Bristol-Myers Squibb (United States)), Shalabh Singhal(Integrated BioTherapeutics (United States)), Elizabeth Ludwig(Cognizant (United States)), Ang Liu(Bristol-Myers Squibb (United States)), Hannah Huang(Simulations Plus (United States)), Huadong Sun(Bristol-Myers Squibb (United States)), Diane E. Shevell(Bristol-Myers Squibb (United States)), Aberra Fura(Bristol-Myers Squibb (United States))
Cited by 6
Related Papers
Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase <scp>II</scp>, Randomized, <scp>Double‐Blind</scp>, <scp>Placebo‐Controlled</scp> Trial
|Arthritis & Rheumatology|2022|261
Outcomes of Neonates Born to Mothers With Severe Acute Respiratory Syndrome Coronavirus 2 Infection at a Large Medical Center in New York City
|Archives of Pediatrics and Adolescent Medicine|2020|255
Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis
|Annals of the Rheumatic Diseases|2022|212
Risk of Major Bleeding with Concomitant Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients Receiving Long‐Term Warfarin Therapy
|Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy|2007|93
Attribution of the discrepancy between ELISA and LC-MS/MS assay results of a PEGylated scaffold protein in post-dose monkey plasma samples due to the presence of anti-drug antibodies
|Analytical and Bioanalytical Chemistry|2011|63